ロード中...
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
BACKGROUND: Dasatinib is a small molecule kinase inhibitor that has recently been shown to inhibit Src family kinases (SFK) and also has activity against CaP. Of importance to metastatic CaP, which frequently metastasises to bone, SFK are also vital to the regulation of bone remodelling. We sought t...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2720213/ https://ncbi.nlm.nih.gov/pubmed/19603032 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605178 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|